Organovo appoints Vaidehi Joshi to Board of Directors as Class I Director

VivoSim Labs, INC.

Appointment effective March 8, 2022; term expires at 2024 annual meeting.
Joshi brings bioprinting and drug discovery experience from Viscient Biosciences and prior Organovo role.
Compensation: $50,000 annual retainer (pro-rated) and initial option grant of 35,000 shares at $3.47.
Option vests quarterly over 12 quarters; accelerated on change of control.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Vaidehi Joshi

Class I Director

VIVS · VivoSim Labs, INC.

Effective: 2022-03-08
Filed: March 10, 2022, 6:59 PM ET

Effective March 8, 2022, the Board of Directors (the “Board”) of Organovo Holdings, Inc. (the “Company”) appointed Vaidehi Joshi to the Board as Class I Director.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Vaidehi Joshi was appointed as Class I Director at VivoSim Labs, INC..

Action: appointed
Role: Class I Director

Exact text from the filing

Effective March 8, 2022, the Board of Directors (the “Board”) of Organovo Holdings, Inc. (the “Company”) appointed Vaidehi Joshi to the Board as Class I Director.

View on SEC.gov

VivoSim Labs, INC. filing history →

Source: SEC EDGAR

accession 0001564590-22-009633

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.